Omeros Corp OMER
Omeros Corp (Nasdaq: OMER) is a hematology drug developer. Its lead program, YARTEMLEA (narsoplimab-wuug), is in Phase 1 for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Its next catalyst on record is OMS527: Start enrollment in in-patient clinical trial in cocaine use disorder (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: OMS527 — Start enrollment in in-patient clinical trial in cocaine use disorder (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| YARTEMLEA (narsoplimab-wuug) | TA-TMA in adults and children aged 2 and older | antibody | Approved |
| OMS1029 | long-acting MASP-2 antibody; Phase 2 indication being selected | antibody | Phase 1 |
| OMS527 (PDE7 inhibitor) | cocaine use disorder | small molecule | Phase 1 |
| MASP-2 oral small molecule | — | small molecule | Pre-clinical |
| OncotoX-AML (OMS805) | acute myeloid leukemia | biologic-other | Pre-clinical |
| T-CAT platform | bacterial, fungal, viral and parasitic infections | antibody | Pre-clinical |
Recent results and decisions
- Oct 30, 2026approval Company achieved FDA approval of YARTEMLEA in 2025.
The Committee determined that the Performance Award is in the best interests of the Company and that its terms are appropriate in light of Dr. Demopulos' role in driving transformative change for the Company in 2025, including achieving FDA approval of YARTEMLEA
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.